^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Caprin-1 inhibitor

    Related drugs:
    1d
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=49, Recruiting, Toray Industries, Inc | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • TRK-950
    2ms
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Toray Industries, Inc | Phase classification: P1 --> P1/2 | N=13 --> 49
    Phase classification • Enrollment change
    |
    Opdivo (nivolumab) • TRK-950
    5ms
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Toray Industries, Inc | Trial completion date: Jun 2025 --> Dec 2027 | Trial primary completion date: Jun 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • TRK-950
    5ms
    Phase I first-in-human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors. (PubMed, Cancer Res Commun)
    TRK-950 is safe and well tolerated, has a favorable PK profile, and should be further investigated as a monotherapy and in combination with standard treatment for various types of solid tumors.
    P1 data • Journal
    |
    CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    TRK-950
    6ms
    Radiopharmaceutical application of TRK-950, an anti-CAPRIN-1 therapeutic antibody. (PubMed, J Cancer Res Clin Oncol)
    This study demonstrates that radiopharmaceuticals targeting CAPRIN-1, including radiolabeled TRK-950 and TRK-950-F(ab')2, have high potential as radiopharmaceuticals.
    Journal
    |
    CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    TRK-950
    8ms
    Development and validation of an antidrug antibody assay for TRK-950 using Melon™ gel and SPEAD pretreatment. (PubMed, Bioanalysis)
    Clinical trials (NCT05423262) employing this improved analytical method have been conducted, and the results confirm the low immunogenicity of TRK-950. The combination of pretreatment with Melon™ gel and SPEAD is applicable for clinical ADA assays.
    Journal
    |
    CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    TRK-950
    8ms
    A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=187, Active, not recruiting, Toray Industries, Inc | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950
    9ms
    A Study of TRK-950 in Patients with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Toray Industries, Inc | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Feb 2025 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • TRK-950
    10ms
    A Study of TRK-950 When Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer (clinicaltrials.gov)
    P2, N=146, Recruiting, Toray Industries, Inc | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CAPRIN1 (Cell Cycle Associated Protein 1)
    |
    paclitaxel • Cyramza (ramucirumab) • TRK-950
    over1year
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Toray Industries, Inc | Recruiting --> Active, not recruiting | N=19 --> 13
    Enrollment closed • Enrollment change • Metastases
    |
    Opdivo (nivolumab) • TRK-950
    almost2years
    A Study of TRK-950 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=19, Recruiting, Toray Industries, Inc | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • TRK-950
    almost2years
    A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=187, Recruiting, Toray Industries, Inc | Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium • Zyclara (imiquimod) • TRK-950